Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.

British Journal of Haematology
Ronan T SwordsBruno C Medeiros

Abstract

This trial was conducted to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the first in class NEDD8-activating enzyme (NAE) inhibitor, pevonedistat, and to investigate pevonedistat pharmacokinetics and pharmacodynamics in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Pevonedistat was administered via a 60-min intravenous infusion on days 1, 3 and 5 (schedule A, n = 27), or days 1, 4, 8 and 11 (schedule B, n = 26) every 21-days. Dose escalation proceeded using a standard '3 + 3' design. Responses were assessed according to published guidelines. The MTD for schedules A and B were 59 and 83 mg/m(2) , respectively. On schedule A, hepatotoxicity was dose limiting. Multi-organ failure (MOF) was dose limiting on schedule B. The overall complete (CR) and partial (PR) response rate in patients treated at or below the MTD was 17% (4/23, 2 CRs, 2 PRs) for schedule A and 10% (2/19, 2 PRs) for schedule B. Pevonedistat plasma concentrations peaked after infusion followed by elimination in a biphasic pattern. Pharmacodynamic studies of biological correlates of NAE inhibition demonstrated target-specific activity of pevonedistat. In conclusion, administration of the first-in...Continue Reading

References

Apr 17, 1999·The Journal of Biological Chemistry·L Gong, E T Yeh
Mar 14, 2000·Molecular and Cellular Biology·M A ReadV J Palombella
Apr 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·V N PodustV Chau
Apr 20, 2001·Proceedings of the National Academy of Sciences of the United States of America·M GstaigerW Krek
Jan 1, 2003·Seminars in Cancer Biology·Joanna Bloom, Michele Pagano
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Jun 8, 2004·Current Protein & Peptide Science·Tomoki Chiba, Keiji Tanaka
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Varuni KondaguntaRobert J Motzer
Feb 3, 2005·Nature Reviews. Molecular Cell Biology·Matthew D Petroski, Raymond J Deshaies
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Sep 27, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard I FisherAndré Goy
Nov 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael P FanucchiJoan H Schiller
May 15, 2007·Circulation Research·Joerg HerrmannAmir Lerman
Jun 5, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven P TreonAshraf Badros
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Dec 17, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoyR I Fisher
Mar 18, 2009·British Journal of Haematology·Alan K BurnettUNKNOWN United Kingdom National Cancer Research Institute Haematological Oncology Study Group
Apr 11, 2009·Nature·Teresa A SoucySteven P Langston
Jun 11, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Teresa A SoucyMark Rolfe
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettRobert K Hills
Jun 4, 2010·Pigment Cell & Melanoma Research·Guangdi ChenGang Li
Sep 30, 2010·International Journal of Oncology·Guangdi Chen, Gang Li
Jan 12, 2011·Expert Opinion on Therapeutic Targets·Meng WangRonan T Swords
Jan 18, 2011·Journal of Psychosocial Oncology·Edwin D BoudreauxGenerosa Grana
Jul 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Olivia Y HungJohn S Kauh
Jul 23, 2011·Genes & Cancer·Teresa A SoucyJames E Brownell

❮ Previous
Next ❯

Citations

Mar 15, 2016·Blood Reviews·Danielle Shafer, Steven Grant
Mar 16, 2016·Proceedings of the National Academy of Sciences of the United States of America·Paul C SchererFeng Rao
Mar 19, 2016·Cell Death and Differentiation·H-S ParkY-S Chun
Nov 20, 2015·Cell Death & Disease·F S Wolenski, Y P Dragan
May 7, 2016·Blood·Kapil N Bhalla, Warren Fiskus
May 11, 2016·Proceedings of the National Academy of Sciences of the United States of America·Xiaochen ZhouYi Sun
Jun 7, 2016·Critical Reviews in Oncology/hematology·Jing LiuGuo-Jun Zhang
Jun 28, 2016·Nature Structural & Molecular Biology·Zhongying MoXiang-Lei Yang
Aug 23, 2016·Genes·Jun ZhangXingming Deng
Sep 3, 2016·Blood·Steven Grant
Apr 29, 2014·Pharmacology & Therapeutics·Prithviraj BoseSteven Grant
Nov 7, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Chien-Chun Steven PaiMehrdad Abedi
Nov 11, 2016·Expert Opinion on Pharmacotherapy·Elena TentiGiovanni Martinelli
Feb 1, 2017·Leukemia & Lymphoma·Prithviraj BoseMarina Konopleva
Aug 14, 2018·Veterinary and Comparative Oncology·A L F V AssumpçãoX Pan
Jan 12, 2019·Current Opinion in Hematology·Namrata S ChandhokThomas Prebet
Jan 15, 2019·Current Opinion in Hematology·Alice S Mims, William Blum
Dec 27, 2018·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kazuma SekibaKazuhiko Koike
Mar 15, 2019·Journal of Internal Medicine·M Tobiasson, A O Kittang
Sep 12, 2017·Nature Chemical Biology·Xingyue HeSai M Pulukuri
Aug 24, 2018·F1000Research·Justin Watts, Stephen Nimer
Jul 30, 2019·Expert Review of Hematology·Ulrich GermingNorbert Gattermann
Dec 23, 2016·The EMBO Journal·Veronika ReitererHesso Farhan
Mar 12, 2019·Current Topics in Medicinal Chemistry·Lina YinQingzhong Hu
Oct 6, 2017·Journal of Biochemistry·Tomohisa SakaueShigeki Higashiyama
Oct 1, 2019·British Journal of Haematology·Pierre FenauxLionel Ades
Jun 2, 2016·American Society of Clinical Oncology Educational Book·Rami S Komrokji
Feb 16, 2020·Cancers·Rishil J KathawalaSteffan T Nawrocki
Jan 8, 2020·Cell Biology and Toxicology·Yanyu JiangLijun Jia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.